ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.3284+1G>C

dbSNP: rs864622129
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000459518 SCV000546811 likely pathogenic Ataxia-telangiectasia syndrome 2023-08-16 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 22 of the ATM gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with ataxia-telangiectasia, colorectal cancer, and/or melanoma (PMID: 21665257, 32658311, 34262154). ClinVar contains an entry for this variant (Variation ID: 407539). Studies have shown that disruption of this splice site results in skipping of exon 22 and introduces a premature termination codon (Invitae). The resulting mRNA is expected to undergo nonsense-mediated decay. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Ambry Genetics RCV002323709 SCV002607007 likely pathogenic Hereditary cancer-predisposing syndrome 2021-09-02 criteria provided, single submitter clinical testing The c.3284+1G>C intronic variant results from a G to C substitution one nucleotide after coding exon 21 of the ATM gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic.
Myriad Genetics, Inc. RCV004022645 SCV004933958 likely pathogenic Familial cancer of breast 2024-01-19 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.